Highlights

  • Analysts issue mixed hold, buy, and outperform ratings on argenx shares.
  • Brokerage firms update views following earnings and revenue announcements.
  • Consensus rating remains Moderate Buy across twenty-four covering firms.

MarketBeat Ratings reports that argenx SE (NASDAQ:ARGX) holds an average rating of “Moderate Buy.” This assessment comes from twenty-four brokerages currently following the biotechnology company. Of these:

  • Four analysts issued hold ratings.
  • Nineteen analysts assigned buy ratings.
  • One firm issued a strong buy rating.

The average 12-month target price reported by analysts who updated coverage in the past year stands at USD 907.6667.
The ratings reflect varied evaluations of the company’s therapeutic pipeline and financial results.

Recent Analyst Commentary

Several research firms have released updated reports:

  • Guggenheim reiterated a buy rating with a USD 1,070.00 target on September 18.
  • Wolfe Research reaffirmed a peer perform rating on November 24.
  • Zacks Research downgraded the stock from strong-buy to hold on October 21.
  • Wedbush raised its target from USD 880.00 to USD 1,000.00, issuing an outperform rating on November 14.
  • Royal Bank of Canada increased its target from USD 850.00 to USD 860.00, also assigning an outperform rating on October 31.

These updates show continued monitoring of argenx’s clinical programs and product pipeline developments.

Earnings Update

argenx released its quarterly earnings on October 30. Key financial details include:

  • Earnings per share: USD 4.40
  • Consensus estimate: USD 4.37
  • Revenue: USD 1.12 billion
  • Analyst expectation: USD 1.07 billion

Additional metrics:

Analysts project full-year EPS of 3.13.

Company Overview

argenx SE is a biotechnology firm developing therapies targeting autoimmune conditions across multiple regions, including the United States, Europe, and Asia.

Shares of ARGX last traded at USD 901.17 on December 05, 2025.